Crucell to Release Q2 2008 Earnings on Tuesday, August 12, 2008

* Reuters is not responsible for the content in this press release.

Tue Aug 5, 2008 8:07am EDT 

  LEIDEN, NETHERLANDS, Aug 05 (MARKET WIRE) -- 

Leiden, The Netherlands (August 5, 2008) - Dutch biopharma company
Crucell N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX) today
announced that it will release its financial results for the second
quarter of 2008 on Tuesday, August 12, 2008 at 07:45 Central European
Time (CET).

    At 14:00 Central European Time (CET), Crucell's management will conduct a
conference call, which will also be webcast. To participate in the
conference call, please call one of the following telephone numbers 10
minutes prior to the event:


                    +44 203 023 4471 for the UK;
                   +1 646 843 4608 for the US; and
                 +3120 794 8426 for the Netherlands

    
Following a presentation of the results, the lines will be opened for
a question and answer session.

    The live audio webcast can be accessed via the homepage of Crucell's
website at www.crucell.com and will be archived and available for replay
following the event.

    About Crucell

    Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) is a global
biopharma company focused on research, development, production and
marketing of vaccines, proteins and antibodies that prevent and treat
primarily infectious diseases. Its vaccines are sold in public and
private markets worldwide. Crucell's core portfolio includes a vaccine
against hepatitis B, a fully-liquid vaccine against five important
childhood diseases and a virosome-adjuvanted vaccine against influenza.
Crucell also markets travel vaccines, such as the only oral anti-typhoid
vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A
vaccine on the market. The Company has a broad development pipeline, with
several product candidates based on its unique PER.C6(R) production
technology. The Company licenses its PER.C6(R) technology and other
technologies to the biopharmaceutical industry. Important partners and
licensees include DSM Biologics, sanofi-aventis, Novartis, Wyeth and
Merck & Co. Crucell is headquartered in Leiden, the Netherlands, with
subsidiaries in Switzerland, Spain, Italy, Sweden, Korea and the US. The
Company employs over a 1000 people. For more information, please visit
www.crucell.com.

    Forward-looking statements

    This press release contains forward-looking statements that involve
inherent risks and uncertainties. We have identified certain important
factors that may cause actual results to differ materially from those
contained in such forward-looking statements. For information relating to
these factors please refer to our Form 20-F, as filed with the U.S.
Securities and Exchange Commission on May 7, 2008, and the section
entitled "Risk Factors". The Company prepares its financial statements
under International Financial Reporting Standards (IFRS).

    For further information please contact:


Crucell N.V.
Oya Yavuz
Director Corporate Communications & Investor Relations
Tel. +31-(0)71-519 7064
ir@crucell.com
www.crucell.com

    






Copyright Copyright Hugin AS 2008. All rights reserved.

    



Copyright 2008, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.